Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
JMP Securities Maintains Market Outperform Rating for Seagen: Here's What You Need To Know
Via Benzinga
Why Boston Beer Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers TravelCenters of America Inc. (NASDAQ: TA) shares jumped 70.5% to $84.32 after BP announced it will acquire the company for $86 per share in cash. 
Via Benzinga
Why Seagen Stock Is Soaring Today
Investors and analysts liked what they heard in the company's Q4 update. 
Via The Motley Fool
Seagen (SGEN) Q4 2022 Earnings Call Transcript
SGEN earnings call for the period ending December 31, 2022. 
Via The Motley Fool
8 Analysts Have This to Say About Seagen
Via Benzinga
Analyst Ratings for Seagen
Via Benzinga
Analysts Are Bullish On Seagen's Catalyst-Rich Pipeline, Finding No Problem With No M&A
Via Benzinga
KBR, Twilio, Roku And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones dropping over 250 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out
Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev. 
Via Investor's Business Daily
Pagaya Technologies To Rally Around Over 120%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc boosted the price target for Twilio Inc. (NYSE: TWLO) from $77 to $89. Keybanc analyst Thomas Blakey maintained an Overweight rating on the stock. Twilio shares gained 6.4% to close at $66.05... 
Via Benzinga
Seagen Reports Fourth Quarter and Full Year 2022 Financial Results
From Seagen Inc.
Via Business Wire
2 Under-the-Radar Biotech Stocks to Buy in 2023
These stocks may soon start turning heads with their revenue growth. 
Via The Motley Fool
Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
From Seagen Inc.
Via Business Wire
RH To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Monday
Citigroup boosted the price target for RH (NYSE: RH) from $305 to $380. Citigroup analyst Steven Zaccone maintained a Buy rating. Hershey shares fell 4% to $330.00 in pre-market trading. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023
Via Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Union Pacific To Rally Over 11%? Here Are 10 Other Analyst Forecasts For Wednesday
Keybanc raised the price target for Reliance Steel & Aluminum Co. (NYSE: RS) from $225 to $235. Keybanc analyst Philip Gibbs maintained an Overweight rating. Reliance Steel shares fell 0.2% to close at... 
Via Benzinga
Seagen's Tukysa Becomes First FDA-Approved Treatment For HER2-Positive Metastatic Colorectal Cancer
Via Benzinga
Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
From Seagen Inc.
Via Business Wire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. 
Via Benzinga
Seagen to Present at the J.P. Morgan Healthcare Conference
From Seagen Inc.
Via Business Wire
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Why Seagen Stock Is Trading Higher During Monday's Session
Seagen Inc (NASDAQ: SGEN) shares are trading higher by 4.79% to $129.94 by after the company announced results from the Phase 2 clinical trial of ADCETRIS with novel immunotherapy combination in... 
Via Benzinga
Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
2 Growth Stocks to Buy if the Bear Market Continues in 2023
These stocks aren't bargain buys just yet, but they could be soon. 
Via The Motley Fool
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting
From Seagen Inc.
Via Business Wire
Imago BioSciences Catapults To Record High On Merck's $1.35 Billion Buyout
Seagen who? Merck is putting its cash to work buying a smaller biotech company. 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.